Introduction: To date, several emerging biomarkers have gained considerable interest in the field of predictive molecular oncology. The advent of precision medicine has led to the development of innovative drugs targeting rare molecular pathways independently from histology, defined as tissue-agnostic drugs.
Areas Covered: Although there is a lot of promise for this new tissue-agnostic model in the oncological scenario, crucial issues from both the diagnostic and therapeutic standpoint are emerging. This review aims to critically examine the role of tissue-agnostic biomarkers in different solid tumors, focusing on the prevalence and methods of detection of agnostic biomarkers together with drug approvals to guide clinicians in this evolving landscape.
Expert Opinion: To strengthen the framework for tissue-agnostic approvals, the dialogue between regulatory, industrial, and academic parties should be intensified. Critical questions include the development of an efficient network system that can overcome the heterogeneity of patients' inclusion criteria along with the increasingly difficult interpretation of next-generation sequencing (NGS) profiling technologies. Cost-effectiveness and risk-benefit studies are needed in the national context considering the modalities of access to diagnostic tests and reimbursement of treatments.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14737159.2023.2245752 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
If it is a solid tumor target, then it may be a hematologic cancer target: Bridging the great divide.
Med
January 2025
Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA; WIN Consortium, Paris, France; University of Nebraska, Omaha, NE, USA. Electronic address:
Tumor-agnostic US Food and Drug Administration approvals are transforming oncology. They include larotrectinib/entrectinib/repotrectinib (NTRK fusions), selpercatinib (RET fusions), dabrafenib/trametinib (BRAF mutations), pembrolizumab/dostarlimab (microsatellite instability), pembrolizumab (high tumor mutational burden), and trastuzumab deruxtecan (HER2 3+ expression) (all solid cancers). Pemigatinib is approved for FGFR1-rearranged myeloid/lymphoid neoplasms.
View Article and Find Full Text PDFLetter to the Editor regarding 'Clinical validation of a tissue-agnostic genome-wide methylome enrichment molecular residual disease assay for head and neck malignancies' by G Liu et al.
Ann Oncol
November 2024
Department of Medical Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian, P. R. China; The Key Laboratory of Biomarker High Throughput Screening and Target Translation of Breast and Gastrointestinal Tumor, Dalian University, Dalian, P. R. China; Liaoning Provincial Radioactive Particle and Thermal Therapy Precision Laboratory, Dalian, P. R. China. Electronic address:
Histology Agnostic Drug Development: An Updated Review.
Cancers (Basel)
October 2024
Touro University Nevada College of Osteopathic Medicine, 874 American Pacific Dr, Henderson, NV 89014, USA.
Recent advancements in oncology have led to the development of histology-agnostic therapies, which target genetic alterations irrespective of the tumor's tissue of origin. This review aimed to provide a comprehensive update on the current state of histology-agnostic drug development, focusing on key therapies, including pembrolizumab, larotrectinib, entrectinib, dostarlimab, dabrafenib plus trametinib, selpercatinib, trastuzumab deruxtecan, and reprotrectinib. We performed a detailed analysis of each therapy's mechanism of action, clinical trial outcomes, and associated biomarkers.
View Article and Find Full Text PDFRedefining pancreatic cancer management with tumor-agnostic precision medicine.
Carcinogenesis
November 2024
Early-Phase Drug Development, Sarah Cannon Research Institute, 335 24th Avenue North Suite 300, Nashville, TN 37203, United States.
Precision oncology and tumor-agnostic drug development provide hope for enhancing outcomes among patients with pancreatic cancer. Tumor-agnostic therapies have emerged across various tumor types, driven by insights into shared biomarkers. In the case of pancreatic cancer, the prevalence of the KRAS gene mutation is noteworthy.
View Article and Find Full Text PDFFirst-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors.
Signal Transduct Target Ther
November 2024
Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai, China.
Article Synopsis
- Oncogenic RET alterations are key targets in various cancers, leading to a phase 1 study of the RET inhibitor SY-5007 in patients with RET-altered solid tumors, focusing on safety, maximum tolerated dose, and efficacy.
- The study involved 122 patients across different cancer types, revealing a high rate of treatment-related adverse events (96.7%), particularly hypertension and diarrhea, alongside a promising overall response rate of 57.8%.
- SY-5007 demonstrated notable efficacy regardless of prior treatments, with median progression-free survival of 21.1 months; circulating tumor DNA analysis indicated that monitoring RET alterations could inform treatment responses and resistance.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!